Elagolix shows long-term efficacy
May 16, 2018|Ob.Gyn. News
REPORTING FROM ACOG 2018
Currently, Elagolix is under FDA priority review, and if approved will be the first oral endometriosis treatment approved in over a decade, according to Dr. Surrey.
Dr. Surrey and several coauthors receive financial support from AbbVie as consultants, board members, and/or employees. Dr. Surrey and Dr. Taylor receive additional support from companies including Pfizer, Bayer, and Obseva.
SOURCE: Surrey ES et al. ACOG 2018, Abstract 11OP.
